

Resource Summary Report

Generated by [NIF](#) on Sep 5, 2026

BALB/cOlaHsd

RRID:MGI:3047778

Type: Organism

Proper Citation

RRID:MGI:3047778

Organism Information

URL: <http://www.informatics.jax.org/strain/MGI:3047778>

Proper Citation: RRID:MGI:3047778

Description: laboratory mouse with name BALB/cOlaHsd from MGI.

Species: laboratory mouse

Notes: Strain Type: inbred strain

Catalog Number: 3047778

Database: Mouse Genome Informatics MGI

Database Abbreviation: MGI

Availability: Availability unknown check source stock center

Organism Name: BALB/cOlaHsd

Record Creation Time: 20230227T022112+0000

Record Last Update: 20260905T152014+0000

Ratings and Alerts

No rating or validation information has been found for BALB/cOlaHsd.

No alerts have been found for BALB/cOlaHsd.

Data and Source Information

Source: [Integrated Animals](#)

Usage and Citation Metrics

We found 115 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Dislers A, et al. (2026) Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant. *The Journal of general virology*, 107(3).

Rincón TC, et al. (2026) Human antibodies against West Nile and related orthoflaviviruses. *bioRxiv : the preprint server for biology*.

Pilipenko V, et al. (2026) Active immunization with bacteriophage AP205 VLPs results in reduced amyloid load and microgliosis in 5xFAD female mice. *Naunyn-Schmiedeberg's archives of pharmacology*, 399(3), 4569.

Bissett C, et al. (2026) Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms. *The Journal of experimental medicine*, 223(1).

Hlavá? M, et al. (2026) Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines. *Vaccines*, 14(3).

Meoni P, et al. (2026) Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors. *Molecular cancer therapeutics*, 25(3), 361.

Russo S, et al. (2025) Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. *Journal for immunotherapy of cancer*, 13(11).

Rothen DA, et al. (2025) Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity. *Vaccines*, 13(9).

Falvo P, et al. (2025) Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical models. *Cell death and differentiation*, 32(6), 1000.

Xing Y, et al. (2025) Single-cell spatial transcriptomics reveals pathogenic mechanism of renal fibrosis in imiquimod-induced lupus nephritis in mice. *Biochemistry and biophysics reports*, 43, 102087.

Hagbi-Levi S, et al. (2025) Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFN?-dependent PD-L1. *Frontiers in immunology*, 16, 1502094.

Saris J, et al. (2025) Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer. *Nature communications*, 16(1), 3669.

Pardini A, et al. (2025) Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses. *Viruses*, 17(9).

Parkinson JE, et al. (2025) Generation of a Ym1 deficient mouse utilising CRISPR-Cas9 in CB6 embryos. *Transgenic research*, 34(1), 44.

Bogataj J, et al. (2025) Effect of Bleomycin Hydrolase Expression in Tumor Tissue on the Therapeutic Effectiveness of Electrochemotherapy. *Cancers*, 18(1).

Mata E, et al. (2025) Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C. *NPJ vaccines*, 10(1), 135.

Omerzel M, et al. (2025) Potentiation of Electrochemotherapy by Anti-PD-1 Immunotherapy in Murine Tumors with Distinct Immune Profiles. *Cancers*, 18(1).

Yefet R, et al. (2025) Potent neutralization by antibodies targeting the MPXV A28 protein. *Nature communications*, 16(1), 11455.

Kalni?a Z, et al. (2025) Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies. *FEBS open bio*, 15(8), 1285.

Seyfizadeh N, et al. (2024) Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus. *Journal of biomedical science*, 31(1), 56.